A
Albiruni Ryan Abdul Razak
Researcher at Princess Margaret Cancer Centre
Publications - 253
Citations - 7154
Albiruni Ryan Abdul Razak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 195 publications receiving 5045 citations. Previous affiliations of Albiruni Ryan Abdul Razak include Harvard University & University Health Network.
Papers
More filters
Journal ArticleDOI
Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.
Zev A. Wainberg,Geoffrey I. Shapiro,Giuseppe Curigliano,Stephen Leong,Rebecca Kristeleit,Maria Alsina Maqueda,Carolyn D. Britten,Michele Milella,Mark R. Middleton,Anthony J. Olszanski,Ulka N. Vaishampayan,Jose A. Lopez-Martin,Karen A. Gelmon,Nicoletta Brega,Kristen J. Pierce,Rachelle Perea,Brett E. Houk,Nuzhat Pathan,Ashwin Gollerkeri,Albiruni Ryan Abdul Razak +19 more
TL;DR: An ongoing phase I dose escalation study is enrolling cohorts of 3–6 patients to determine maximum tolerated dose (MTD) and safety of PF384 plus docetaxel, cisplatin, or the EGFR tyrosine kinase inhibitor dacomitinib to overcome resistance to different classes of chemotherapies.
Journal ArticleDOI
Results of a phase I dose escalation and expansion study of tegavivint (BC2059), a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumor.
Lee D. Cranmer,Albiruni Ryan Abdul Razak,Ravin Ratan,Edwin Choy,Suzanne George,David A. Liebner,David D. Stenehjem,Mrinal M. Gounder +7 more
TL;DR: Tegavivint is well tolerated with mostly Grade 1/2 AEs and no serious toxicity associated with WNT inhibition and the ORR of 25% at the RP2D warrants continued development of tegavvint in desmoid tumors.
Journal ArticleDOI
A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).
Sue Richter,Elaine McWhirter,Eric Chen,Ben Tran,Sebastien J. Hotte,Anastasios Stathis,Hal W. Hirte,Albiruni Ryan Abdul Razak,Anne Laughlin,Lisa Wang,Kristina Battista,Lee-Anne Stayner,S. Percy Ivy,Malcolm J. Moore,Amit M. Oza,Lillian L. Siu,Philippe L. Bedard +16 more
TL;DR: A novel oral inhibitor of γ-secretase that disrupts Notch signaling and Gemcitabine is active against many solid tumors with a favorable toxicity profile suited to chemotherapy.
Journal ArticleDOI
Customized autoantibodies (autoAbs) profiling to predict and monitor immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors (ICI).
Sofia Genta,Sareh Keshavarzi,N. Yee,Alya Heirali,Aaron R. Hansen,Lillian L. Siu,Samuel D. Saibil,L-A Stayner,M. Yanekina,Maxwell B. Sauder,Abdulazeez Salawu,Pavlina Spiliopoulou,Olga Vornicova,Maysa Tamara Silveira Vilbert,Mark S. Butler,Philippe L. Bedard,Albiruni Ryan Abdul Razak,Bryan Coburn,Andrzej Chruscinski,Anna Spreafico +19 more
TL;DR: A higher number of IgG with MFI >500 at baseline and a greater increase after ICI administration in individuals with irAEs compared to those without ir AEs was observed and Steroid treatment resulted in a decrease in autoAbs.
Journal ArticleDOI
Forty years of randomized trials in advanced/metastatic soft tissue sarcoma (STS): Endpoint selection, surrogacy and quality of reporting.
TL;DR: A systematic review of MEDLINE and EMBASE identified RCTs of systemic therapy in STS found that quality of reporting of efficacy and toxicity were defined as described previously and trends over time evaluated using simple linear regression.